Can Parasites Cause Diabetes? What the Research Says

Certain parasites are linked to a higher risk of diabetes, while others appear to lower it. A systematic review and meta-analysis of case-control studies found that diabetic patients were roughly 70% more likely to harbor intestinal parasites than non-diabetic controls, but that headline number hides a much messier story. The relationship between parasites and diabetes runs in both directions, depends heavily on the type of parasite involved, and in some cases may even flip from harmful to protective. The research is still catching up to the complexity.

Parasites Linked to Higher Diabetes Risk

The strongest evidence connecting a specific parasite to diabetes involves Toxoplasma gondii, the single-celled organism best known for its association with cats. A meta-analysis of human case-control studies found that the overall prevalence of T. gondii infection was about 48% among people with type 2 diabetes, compared with roughly 26% in healthy controls, yielding an odds ratio of 2.32.¹ A separate meta-analysis focused on type 1 diabetes found a similar signal: after removing one statistical outlier, the pooled odds ratio rose to 3.38.² These are associations, not proof of causation, but the consistency across multiple study populations in different countries has kept researchers interested.

Not all intestinal parasites point in the same direction. In a cross-sectional study of adults in Laos, infection with Taenia (tapeworm) was positively associated with higher blood sugar markers and nearly triple the odds of diabetes, while no other worm species in the study showed the same link.³ The broader meta-analysis of intestinal parasites and diabetes, pooling case-control studies, confirmed that people with diabetes carry a statistically higher burden of gut parasites overall, with an odds ratio of 1.72.⁴ But this aggregate number lumps together parasites that may have very different biological effects, which is part of why the field remains unsettled.

How Toxoplasma May Damage the Pancreas

Researchers have not settled whether Toxoplasma gondii infection leads to diabetes, whether diabetes makes people more vulnerable to the parasite, or whether both happen at once. But animal experiments have provided at least one plausible mechanism for how the parasite could push someone toward diabetes. In chronically infected mice, researchers found fewer and smaller insulin-producing clusters (islets) in the pancreas, along with immune cells infiltrating the remaining islets and signs of programmed cell death. The infected mice also showed reduced insulin production and higher blood sugar, though full-blown diabetes did not develop during the study period.⁵

A study of type 1 diabetic patients found that about 42% of those with a family history of the disease tested positive for T. gondii antibodies, raising the possibility that the parasite acts as an environmental trigger in people already genetically predisposed.⁶ The idea is that chronic infection sparks a sustained immune response that gradually destroys beta cells in the pancreas, similar to how certain viruses are suspected to trigger type 1 diabetes. Whether this mechanism operates meaningfully in humans, at the scale needed to explain population-level diabetes rates, is an open question.

Chagas Disease and Pancreatic Beta Cells

Trypanosoma cruzi, the parasite behind Chagas disease, offers a different angle. This organism does not appear to destroy insulin-producing cells outright. Instead, a review of human and animal studies found that infection alters how beta cells respond to sugar signals, dampening their ability to release insulin properly. The change seems to involve the internal machinery of the cell rather than the death of the cell itself.⁷ Whether this blunted insulin release tips Chagas patients into clinical diabetes over time remains unconfirmed, but the concern is real enough that researchers continue to flag it as a potential long-term complication of the disease.

There are also rare case reports of parasitic cysts physically occupying the pancreas and destroying tissue. A hydatid cyst (from the tapeworm Echinococcus) lodged in the pancreas was documented to cause ductal obstruction, tissue destruction, and secondary diabetes in one patient. These cases are unusual enough to be publishable individually, but they illustrate that parasites can reach the pancreas through direct invasion, not just through immune disruption.

The Surprising Protective Side of Worm Infections

Here is where the story takes a counterintuitive turn. Several species of helminths (parasitic worms) appear to lower the risk of type 2 diabetes rather than raise it. The most striking example comes from a cross-sectional study in rural China, where people with a history of schistosome infection had significantly lower fasting blood sugar, post-meal blood sugar, and insulin resistance compared with uninfected controls. The prevalence of diabetes was about 15% in the previously infected group versus 25% in the uninfected group, and the odds of diabetes were cut roughly in half.⁸

This is not an isolated finding. Population studies across Indonesia, Australia, and other helminth-endemic settings have reported that soil-transmitted worm infections correlate with lower insulin resistance, sometimes in a dose-dependent pattern: the more worm species a person carried, the lower their insulin resistance tended to be.⁹ A review of the evidence identified Schistosoma, Nippostrongylus, Strongyloides, and Heligmosomoides as helminth species that may slow or reduce type 2 diabetes progression in both human and animal models, with the proposed mechanism centering on improved insulin sensitivity and reduced inflammation.¹⁰

The biological explanation has to do with how worms manipulate the immune system. Chronic helminth infections shift the body’s immune response away from the kind of aggressive, inflammatory state that drives insulin resistance. Research on people co-infected with Strongyloides stercoralis and type 2 diabetes found that the worm infection was associated with dampened levels of circulating inflammatory molecules that are normally elevated in diabetes, providing a plausible biological bridge between the epidemiological observations and the immune system.¹¹

Worms and Type 1 Diabetes in Animal Models

The protective effects extend to type 1 diabetes as well, at least in laboratory mice. Non-obese diabetic (NOD) mice, which are bred to develop autoimmune diabetes, were protected from the disease when infected with filarial worms. The protection was linked to an increase in regulatory T cells, which are immune cells that keep the body’s attack forces in check and prevent them from targeting the pancreas.¹² Proteins secreted by the liver fluke Fasciola hepatica achieved a similar effect, preventing diabetes in NOD mice by encouraging the growth of those same regulatory T cells.¹³

Researchers have even tested a combination therapy that pairs worm antigens (proteins from the worm’s surface) with proinsulin, a diabetes-specific immune target. In NOD mice that had already developed early pancreatic inflammation, neither treatment worked alone, but the combination prevented diabetes onset and reduced the immune assault on the pancreatic islets.¹⁴ These are mouse studies, and the leap to human therapy is enormous, but they point toward a real therapeutic concept: that components of parasitic worms could one day be harnessed as anti-inflammatory treatments for autoimmune diseases, including diabetes.¹⁵

What Happens When You Deworm People

If worm infections protect against insulin resistance, what happens when you treat the worms? A cluster-randomized trial in Indonesia gave albendazole (a common deworming drug) to communities and then tracked metabolic changes. At the community level, there was no effect on insulin resistance. But among people who actually had worm infections at the start of the trial, deworming led to a measurable increase in insulin resistance.¹⁶ A companion analysis of the same trial found that deworming shifted the balance of two hormones involved in metabolism: adiponectin (which improves insulin sensitivity) dropped, and the ratio of leptin to adiponectin climbed, partly explaining the increase in insulin resistance.¹⁷

This does not mean deworming is bad for you. Intestinal worms cause malnutrition, anemia, stunted growth in children, and a range of other serious problems. The metabolic findings are a reminder that the immune and metabolic changes worms produce are real and not trivially replaced once the worms are gone. For public health programs in endemic areas, the takeaway is that deworming campaigns may need to account for metabolic consequences, particularly in populations already at high risk for type 2 diabetes.

The Hygiene Hypothesis and Evolutionary Context

The idea that losing our parasites might make us sicker in certain ways fits into a broader concept sometimes called the hygiene hypothesis or, more accurately, the “old friends” hypothesis. Humans co-evolved with helminths for hundreds of thousands of years, and our immune systems developed in the constant presence of these organisms. One proposal suggests that the immune-dampening effects of helminths were part of the background conditions under which human metabolism evolved, and that removing those organisms without replacing their immune effects leaves us more prone to inflammatory and autoimmune conditions, including both type 1 and type 2 diabetes.¹⁸

Pinworms, for instance, are mostly harmless and often cause no symptoms, yet they inhibit diabetes development in NOD mice. Their sharp decline in wealthy countries with improved sanitation coincides with the rise of autoimmune diseases including type 1 diabetes and asthma. Some researchers have argued that cardiovascular disease and type 2 diabetes were not major causes of adult illness for most of human evolutionary history, when inflammation was driven by pathogens rather than by the kind of chronic, low-grade, sterile inflammation that characterizes modern metabolic disease.¹⁹ The evidence is suggestive rather than conclusive, but it provides a conceptual framework for why the parasite-diabetes connection runs in such contradictory directions depending on the species involved.

Malaria and Blood Sugar Swings

Malaria complicates glucose metabolism in a very different way from the parasites discussed above. Rather than pushing blood sugar up, severe falciparum malaria frequently causes dangerously low blood sugar. The malaria parasite Plasmodium falciparum is a voracious consumer of glucose: infection can increase the rate at which a red blood cell burns through sugar by up to 100-fold.²⁰ This massive glucose demand, combined with impaired glucose production by the liver, creates a setup for hypoglycemia that is compounded when patients are treated with quinine, which stimulates the pancreas to release insulin.²¹

This means malaria’s effect on blood sugar is essentially the opposite of diabetes during acute illness. However, the metabolic stress of severe or repeated malaria episodes over a lifetime, and the inflammation they provoke, could theoretically contribute to long-term metabolic disruption. The evidence for malaria as a driver of chronic diabetes is thin compared with the evidence for Toxoplasma or helminths, but the acute glucose effects are well established and clinically important for anyone managing diabetes in malaria-endemic regions.

When Diabetes Makes Parasites Worse

The relationship is not always about parasites causing diabetes. Sometimes diabetes makes parasitic infections more dangerous. Strongyloides stercoralis, a soil-transmitted roundworm, can persist silently in the gut for decades through a self-reinfection cycle. In people with compromised immune systems, the worm can multiply explosively in what is called hyperinfection syndrome, spreading beyond the gut to the lungs, brain, and other organs. Traditionally, the main risk factors for hyperinfection are steroid use and other forms of immunosuppression, but case reports and literature reviews have begun flagging diabetes as a possible independent risk factor.²²

A case report from Romania described a 71-year-old diabetic patient with no other immunosuppressive conditions who developed severe strongyloidiasis with gastric involvement and partial intestinal obstruction. The authors emphasized that diabetes was the only identifiable risk factor in that patient.²³ Type 2 diabetes impairs multiple arms of the immune system, including the ability to mount the kind of immune response needed to keep Strongyloides in check. For people with diabetes living in or traveling to areas where soil-transmitted worms are common, this is a practical concern worth discussing with a doctor, especially before starting any treatment that further suppresses immunity.

A Hidden Lab Pitfall

There is a less obvious way parasites interact with diabetes that has nothing to do with biology and everything to do with measurement. HbA1c, the standard blood test used to gauge long-term blood sugar control, measures how much glucose has attached to hemoglobin in red blood cells over the past two to three months. But the test assumes that red blood cells are behaving normally. Many parasitic infections, especially those that cause chronic blood loss or alter red blood cell turnover, can lower hemoglobin levels or change how quickly red blood cells are replaced. A study of diabetic patients with parasitic infections found that their average HbA1c was 8.9%, compared with 11.5% in diabetic patients without parasitic infection, a significant difference that could easily give a misleading picture of how well-controlled someone’s blood sugar actually is. The hemoglobin levels themselves were similar in both groups, so the HbA1c difference was not simply explained by anemia.²⁴

For clinicians in areas where parasitic infections are common, this is a genuine diagnostic trap. A patient might appear to have well-managed diabetes based on HbA1c when in fact their blood sugar is running much higher. Fasting glucose and post-meal glucose checks can help fill the gap, but only if the clinician is thinking about the possibility that parasites are skewing the standard lab work.

Drug Interactions Between Diabetes Medications and Antiparasitics

People managing diabetes who also need treatment for parasitic infections face potential drug interactions that are only beginning to be studied. An in-lab analysis of how common diabetes and blood-pressure medications affect the liver enzyme responsible for breaking down ivermectin (a widely used antiparasitic) found that metformin on its own had minimal impact on the enzyme. However, hydrochlorothiazide, a blood-pressure medication frequently prescribed alongside diabetes drugs, strongly inhibited the same enzyme, which could slow the clearance of ivermectin and raise its levels in the body.²⁵ These are early-stage findings from cell-based experiments, not clinical trials in people, but they highlight that the overlap between diabetes management and parasite treatment is a space with real pharmacological unknowns. Mass deworming programs in diabetes-heavy populations, or individual treatment decisions in patients on complex medication regimens, could benefit from more research here.

Giardia lamblia, one of the most common intestinal parasites worldwide, adds yet another layer. Research has found that Giardia infection disrupts the lining of the gut, shifts the composition of gut bacteria, and alters immune responses in ways that could impair metabolic health.²⁶ The gut microbiome is increasingly recognized as a player in insulin sensitivity and blood sugar regulation, so a parasite that reshapes the microbial community could have metabolic ripple effects that go well beyond the gut symptoms most people associate with giardiasis. Whether these effects are large enough to contribute to clinical diabetes in otherwise healthy people is still unknown, but it represents an active frontier in the field.